Very good news for the chemo subgroup. They had better numbers than the interim results. So does this mean one of the other subgroups performed relatively poorly compared to this one?

This is very good as it confirms B-OM is extremely effective in Chemotherapy patients. I look forward to seeing the results of the other subgroups. Maybe the weaker subgroups will benefit from a better formulation. Overall this makes me feel more confident in B-OM being the leader in at least part of the HNC market.